Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections

European Respiratory Journal

Volumn 28, Issue 4, 2006, Pages 695-702

  Phua, J ^a   Koay, E S C ^a,b   Zhang, D ^a   Tal, L K ^b   Boo, X L ^a   Lim, K C ^a   Lim, T K ^a,c  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Antibiotics; Asthma; Chronic obstructive pulmonary disease; Pneumonia; Respiratory infections; Soluble form of the triggering receptor expressed on myeloid cells 1

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL 1; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM1 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BONE MARROW CELL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE MARKER; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEPTIC SHOCK; BACTERIAL PNEUMONIA; BLOOD; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASTHMA; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PNEUMONIA, BACTERIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, IMMUNOLOGIC;

EID: 33847381079     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00005606     Document Type: Article

References (30)

1. Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
2. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56: Suppl. 4, S1-S64.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
4. Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health: National Heart, Lung, and Blood Institute. Publication No. NIH-NHLI 02-3659. Bethesda, MD, National Institutes of Health, 2004.
5. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc 2004; 1: 109-114.
6. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
7. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
8. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-217.
9. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21: 939-943.
10. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
11. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006: [Epub ahead of print].
12. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164: 4991-4995.
13. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410: 1103-1107.
14. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350: 451-458.
15. Richeldi L, Mariani M, Losi M, et al. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J 2004; 24: 247-250.
16. Gibot S, Massin F, Le Renard P, et al. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Crit Care Med 2005; 33: 1787-1793.
17. Gibot S, Kolopp-Sarda MN, Bene MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141: 9-15.
18. Gibot S, Cravoisy A, Kolopp-Sarda MN, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-l, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005; 33: 792-796.
19. Gibot S, Le Renard PE, Bollaert PE, et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 2005; 31: 594-597.
20. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-538.
21. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
22. Gibot S. Role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit Care 2005; 9: 485-489.
23. Knapp S, Gibot S, de Vos A, Versteeg HH, Colonna M, van der Poll T. Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol 2004; 173: 7131-7134.
24. Bleharski JR, Kiessler V, Buonsanti C, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 2003; 170: 3812-3818.
25. Gibot S, Massin F. Soluble form of the triggering receptor expressed on myeloid cells 1: an anti-inflammatory mediator? Intensive Care Med 2006; 32: 185-187.
26. Mattson DL, Bellehumeur TG. Comparison of three chemiluminescent horseradish peroxidase substrates for immunoblotting. Anal Biochem 1996; 240: 306-308.
27. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71-78.
28. Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172: 195-199.
29. Jousilahti P, Salomaa V, Hakala K, Rasi V, Vahtera E, Palosuo T. The association of sensitive systemic inflammation markers with bronchial asthma. Ann Allergy Asthma Immunol 2002; 89: 381-385.
30. Ireland N, Kalkoff M, Cursons RT, Sleigh JW. Messenger RNA expression of multiple immune mediators in leukocytes from elective orthopaedic surgical patients. Anaesth Intensive Care 2004; 32: 188-195.